Immune responses and side effects of five different oil-based adjuvants in mice

Veterinary Immunology and Immunopathology

Volumn 61, Issue 2-4, 1998, Pages 291-304

  Leenaars, Marlies ^a,b,c   Koedam, Marianne A ^a   Hendriksen, Coenraad F M ^a   Claassen, Eric ^c,d  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b TNO   (Netherlands)

^c ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^d WAGENINGEN UNIVERSITY   (Netherlands)

Author keywords

Adjuvant; Cytokines; Isotype; Mice; Side effects; Synthetic peptide

Indexed keywords

ADJUVANT; ANTIGEN; FREUND ADJUVANT; GAMMA INTERFERON; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INTERLEUKIN 4; MONTANIDE ISA50; RIBI; SPECOL; TITERMAX; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG SCREENING; FEMALE; HISTOPATHOLOGY; IMMUNE RESPONSE; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; SPLEEN CELL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0032570942     PISSN: 01652427     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-2427(97)00133-5     Document Type: Article

References (31)

1. Bennett, B., Check, I.J., Olsen, M.R., Hunter, R.L., 1992. A comparison of commercially-available adjuvants for use in research. J. Immunol. Meth. 153, 31-40.
2. Boersma, W.J.A., Deen, C., Gerritse, K., Zegers, N.D., Haaijman, J.J., Claassen, E., 1989. Anti-peptide antibodies as a subclass specific reagents: epitope mapping of human IgG2. Prot. Biol. Fluids 36, 161-165.
3. Boersma, W.J.A., Bogaerts, W.J.C., Bianchi, A.T.J., Claassen, E., 1992. Adjuvant properties of stable water-in-oil emulsions; evaluation of the experience with Specol. In: 44th Forum in Immunology. Res. Immunol., 143, 503-512.
4. Bokhout, B.A., van Gaalen, C., van der Heijden, Ph.J., 1981. A selected water-in-oil emulsion: composition and usefulness as an immunological adjuvant. Vet. Immunol. Immunopathol. 2, 491-500.
5. Broderson, J.R., 1989. A retrospective review of lesions associated with the use of Freund's adjuvant. Lab. Anim. Sci. 39, 400-405.
6. Claassen, E., Adler, L., 1988. Sequential double immunocytochemical staining for the in situ study of an auto-anti-allotype immune response in allotype suppressed rabbits. J. Histochem. Cytochem. 36, 1455-1461.
7. Claassen, E., Boersma, W.J.A., 1992. Characteristics and practical use of new-generation adjuvants as an acceptable alternative to Freund's complete adjuvant. In: 44th Forum in Immunology. Res. Immunol., 143, 475-477.
8. Daly, T.M., Long, C.A., 1996. Influence of adjuvants on protection induced by a recombinant fusion protein against malarial infection. Infect. Immun. 64, 2602-2608.
9. Finkelman, F.D., Holmes, J., Katona, I.M., Uraban, J.F., Beckman, M.P., Park, L.S., Schooley, K.A., Coffman, R.L., Mosmann, T.R., Paul, W.E., 1990. Lymphokine control of in vivo immunoglobulin isotype selection. Ann. Rev. Immunol. 8, 303-333.
10. Fox, B.S., 1992. Antibody responses to a cytochrome c peptide do not correlate with lymphokine production patterns from helper T cell subsets. Immunology 75, 164-169.
11. Ganne, V., Eloit, M., Laval, A., Adam, M., Trouve, G., 1994. Enhancement of the efficacy of a replication-de* fective adenovirus-vectored vaccine by the addition of oil adjuvants. Vaccine 12, 1190-1196.
12. Geerligs, H.J., Weijer, W.J., Welling, G.W., Welling-Wester, S., 1989. The influence of different adjuvants on the immune response to a synthetic peptide comprising amino acid residues 9-21 of herpes simplex virus type 1 glycoprotein D. J. Immunol. Meth. 124, 95-102.
13. Grun, J.L., Maurer, P.H., 1989. Different T helper cell subsets elicited in mice utilizing two different adjuvant vehicles: the role of endogenous interleukin-1 in proliferative responses. Cell. Immunol. 121, 134-145.
14. Hunter, R.L., Olsen, M.R., Bennett, B., 1995. Copolymer adjuvants and TiterMax. In: Stewart-Tull, D.E.S. (Ed.), The Theory and Practical Application of Adjuvants, Wiley, Chichester, pp. 51-94.
15. Jones, G.L., Spencer, L., Lord, R., Mollard, R., Pye, D., Saul, A., 1990. Peptide vaccines derived from a malarial surface antigen: effects of dose and adjuvants on immunogenicity. Immunol. Lett. 24, 253-260.
16. Kast, W.M., Brandt, R.M.P., Melief, C.J.M., 1993. Strict peptide length is not required for the induction of cytotoxic T lymphocyte-mediated antiviral protection by peptide vaccination. Eur. J. Immunol. 23, 1189-1192.
17. Kenney, J.S., Hughes, B.W., Masada, M.P., Allison, A.C., 1989. Influence of adjuvants on the quantity, affinity, isotype and epitope specificity of murine antibodies. J. Immunol. Meth. 121, 157-166.
18. Laman, J.D., Claassen, E., 1996. T cell independent and T cell dependent humoral immunity. In: Snapper, C.M. (Ed.), Cytokine Regulation of Humoral Immunity: Basic and Clinical Aspects. Wiley, Chichester, pp. 23-72.
19. Leenaars, P.P.A.M., Hendriksen, C.F.M., Koedam, M.A., Claassen, I., Claassen, E., 1995. Comparison of adjuvants for immunopotentiating properties and side effects in mice. Vet. Immunol. Immunopathol. 48, 123-138.
20. Lipman, N.S., Trudel, L.J., Murphy, J.C., Sahali, Y., 1992. Comparison of immune response potentiation and in vivo inflammatory effects of Freund's and RIBI adjuvants in mice. Lab. Anim. Sci. 42, 193-197.
21. Morton, D.B., Griffiths, P.H.M., 1985. Guidelines on the recognition of pain, distress and discomfort in experimental animals and an hypothesis for assessment. Vet. Rec. 116, 431-436.
22. Ohara, J., Paul, W.E., 1985. Production of a monoclonal antibody to and molecular characterization of B-cell stimulatory factor-1. Nature 315, 333-336.
23. Rudbach, J.A., Johnson, D.A., Ulrich, J.T., 1995. Ribi adjuvants: chemistry, biology and utility in vaccines for human and veterinary medicine. In: Stewart-Tull, D.E.S. (Ed.), The Theory and Practical Application of Adjuvants, Wiley, Chichester, pp. 287-313.
24. Scalzo, A.A., Elliott, S.L., Cox, J., Gardner, J., Moss, D.J., Suhrbier, A., 1995. Induction of protective cytotoxic T cells to murine cytomegalovirus by using nonapeptide and a human-compatible adjuvant (Montanide ISA720). J. Virol. 69, 1306-1309.
25. Tiong, G.K.L., Gill, H.S., Lofthouse, S., Puri, N.K., 1993. Comparison of conventional adjuvants and 'adjuvant-free' monoclonal antibody targeting for stimulating antibody responses against a conjugate of luteinizing hormone releasing hormone and avidin. Vaccine 11, 425-430.
26. Toth, L.A., Dunlap, A.W., Olson, G.A., Hessler, J.R., 1989. An evaluation of distress following intraperitoneal immunisation with Freund's adjuvant in mice. Lab. Anim. Sci. 39, 122-126.
27. Valensi, J.M., Carlson, J.R., Van Nest, G.A., 1994. Systemic cytokine profiles in BALB/c mice immunised with trivalent vaccine containing MF59 oil emulsion and other advanced adjuvants. J. Immunol. 153, 4029-4039.
28. Van den Eertwegh, A.J.M., Noelle, R.J., Roy, M., Shepherd, D.M., Aruffo, A., Ledbetter, J.A., Boersma, W.J.A., Claassen, E., 1993. In vivo CD40-gp39 interactions are essential for thymus-dependent humoral immunity: I. In vivo expression of CD40 ligand, cytokines, and antibody production delineates sites of cognate T-B cell interactions. J. Exp. Med. 178, 1555-1565.
29. Van der Meide, P.H., Borman, A.H., Beijaars, H.G., Dubbeld, M.A., Botman, C.A.D., Schellekens, H., 1989. Isolation and characterization of monoclonal antibodies directed to rat interferon-gamma. Lymphokine Res. 8, 439-449.
30. Vogel, F.R., Powell, M.F., 1995. A compendium of vaccine adjuvants and excipients. In: Powell, M.F., Newman, M.J. (Eds.), Vaccine Design, The Subunit and Adjuvant Approach, Pharmaceutical Biotechnology Series 6, Plenum, New York, pp. 141-228.
31. Zhou, E., Afshar, A., 1995. Comparison of Freund's adjuvant and TiterMax in inducing anti-idiotype to idiotype antibodies against pseudorabies virus antigens. Vet. Immunol. Immunopathol. 48, 113-122.